Company Description
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China.
Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.
NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Dr. Shai N. Gozani M.D., Ph.D. |
Contact Details
Address: 1000 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | (781) 890-9989 |
| Website | neurometrix.com |
Stock Details
| Ticker Symbol | NURO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001289850 |
| CUSIP Number | 641255807 |
| ISIN Number | US6412558800 |
| Employer ID | 04-3308180 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shai N. Gozani M.D., Ph.D. | Founder, Chairman, Chief Executive Officer, President and Secretary |
| Thomas T. Higgins | Senior Vice President, Chief Financial Officer and Treasurer |
| Dr. Xuan Kong Ph.D. | Chief Data Scientist |
| Susan M. Bell R.N. | Senior Vice President of Population Health and Value Based Care |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 8-K | Current Report |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 1, 2024 | SCHEDULE 13D/A | Filing |
| Mar 27, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 1, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K/A | [Amend] Current report |
| Feb 27, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 27, 2024 | 8-K | Current Report |